Clinical Report: FDA approves XFG-adapted COVID-19 vaccine
Overview
The FDA has approved the XFG-adapted COVID-19 vaccine (COMIRNATY) for adults aged 65 and older and for individuals aged 5-64 with underlying conditions. This approval is based on data supporting the vaccine's safety and effectiveness.
Background
The approval of the XFG-adapted COVID-19 vaccine targets a variant identified as a preferred composition for vaccines in the U.S. starting in fall 2026. This decision is based on the ongoing evolution of SARS-CoV-2 variants.
Data Highlights
The approval was based on previously submitted clinical, nonclinical, and real-world data supporting the safety and effectiveness of COMIRNATY.
Key Findings
The XFG-adapted vaccine is approved for adults aged 65 years and older and individuals aged 5-64 with at least one underlying condition.
The approval is based on data showing immune responses against multiple circulating SARS-CoV-2 variants.
More than 5 billion doses of COMIRNATY have been distributed globally.
Severe allergic reactions may occur in patients with a history of such reactions to previous doses of COMIRNATY or other Pfizer-BioNTech vaccines.
Myocarditis and pericarditis have been reported, particularly among males aged 12-24 years.
Common adverse events include injection-site reactions, fatigue, headache, and gastrointestinal symptoms.
Clinical Implications
Healthcare providers should be aware of the updated vaccine formulation and its target populations.
Conclusion
The approval of the XFG-adapted vaccine addresses the evolving landscape of COVID-19 variants.
